Gurdeep Parmar, MBBS, MD, FRCPA, FRACP discusses patient experience and preference findings from the phase 2 IZALCO study evaluating subcutaneous isatuximab administered via on-body injector in relapsed/refractory multiple myeloma.

Isatuximab Subcutaneous (Isa SC) via On-Body Injector (OBI) or Manual Injection for Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience From the Phase 2 IZALCO Study

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Gurdeep Parmar, MBBS, MD, FRCPA, FRACP, discusses patient experience and preference findings from the phase 2 IZALCO study evaluating subcutaneous isatuximab administered via on-body injector in relapsed/refractory multiple myeloma.

Isatuximab Subcutaneous (ISA SC) via On-Body Injector (OBI) or Manual Injection For Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience From the Phase 2 IZALCO Study